




APIs Pipeline

Venetoclax



Venetoclax (CAS-RN 1257044-40-8) is an antineoplastic agent approved in 2016 by US FDA to treat patients with Chronic Lymphocytic Leukemia (CLL).

Venetoclax is a potent and selective inhibitor of the antiapoptotic protein BCL-2 (B-cell lymphoma). It binds directly to the binding site of the BH3 domain of BCL-2 and thereby displaces proapoptotic proteins with BH3 domains, such as BIM, to initiate permeabilization of the mitochondrial outer membrane (MOMP), caspase activation and programmed cell death.

Main Therapeutic Application

ANTINEOPLASTIC

CAS-RN

1257044 - 40 -8

Specification

In House

Documentation

EDMF



+34 93 377 00 51

lebsa@lebsa.com

www.lebsa.com

MADE IN EUROPE

HEADQUARTERS:

Ctra. de l'Hospitalet, 34
08940 Cornellà (Barcelona)
SPAIN

Are you looking for
other molecules?

For more information about our R&D
pipeline and CDMO services

CONTACT US